Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 2 Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Testicular Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Head and Neck Neoplasms 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 HER2-positive Advanced Gastric Cancer 1 HER2 Overexpression 1 Gastrointestinal Stromal Tumors 1 Gastrointestinal Neoplasms 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1

Interventions

pyrotinib 4 neratinib 2 tucatinib 1 trastuzumab deruxtecan 1 pertuzumab 1 Trastuzumab 1 Hospital Information Systems 1 Genetic Testing 1 Electronic Health Records 1 Blood Specimen Collection 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × HER2-positive Breast Cancer × trastuzumab deruxtecan × Clear all

NCT05458401 2024-03-15

EUROPA T-DXd

Daiichi Sankyo

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡